Company intelligence / Profile preview

Meiji Pharma USA

Fort Lee, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Meiji Pharma USA is the United States-based subsidiary of Meiji Seika Pharma Co., Ltd., a prominent Japanese pharmaceutical company. The organization focuses on the clinical development and regulatory approval of innovative therapies, particularly in the fields of neurology and infectious diseases. Its portfolio includes safinamide for the treatment of Parkinson's disease and arbekacin for bacterial pneumonia. Meiji Pharma USA also collaborates with strategic partners to advance next-generation vaccine technologies, such as self-amplifying mRNA platforms.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: Small moleculemRNA-based drugsVaccine
Industry: Biotech

Partnerships

Arcturus TherapeuticsSupernus PharmaceuticalsZambon

Beyond the preview

Go deeper on Meiji Pharma USA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meiji Pharma USA.

Explore the full profile